Heart failure & cardiomyopathiesCohort study

Transthyretin Tetramer Destabilization and Increased Mortality in the General Population

JAMA CardiolPublished

  • Prospective cohort study
  • genetic analyses
  • observational subsample analyses

Authors' conclusion

Transthyretin tetramer destabilization was associated with all-cause and cardiovascular mortality in the Danish general population.

Study context

Population
Individuals aged 20 to 80 years from the Danish general population (Copenhagen City Heart Study (CCHS) and Copenhagen General Population Study (CGPS))
Participants
102,204 individuals
Exposure
TTR genotypes by tetramer stability vs p.T139M stabilizing variant
Outcome
All-cause and CV mortality
Follow-up
Median 10 years

Main finding

As reported in the abstract

Each group vs p.T139MHazard ratio (95% CI)
Noncarriersall-cause mortality
1.37(1.06–1.77)
Amyloidogenic variant heterozygotesall-cause mortality
1.65(0.95–2.88)
NoncarriersCV mortality
1.63(0.92–2.89)
Amyloidogenic variant heterozygotesCV mortality
2.23(0.78–6.34)

Observational data: associations, not effects.

Further findings

OutcomeHR (95% CI)
Mortality by plasma transthyretin <20 vs 20 to 40 mg/dL in noncarriers (observational) — <20 mg/dL vs 20 to 40 mg/dL · all-cause mortality1.12 (1.02–1.23)
Mortality by plasma transthyretin <20 vs 20 to 40 mg/dL in noncarriers (observational) — <20 mg/dL vs 20 to 40 mg/dL · CV mortality1.16 (0.97–1.39)
Outcomedifference
Plasma transthyretin by TTR genotype — Noncarriers vs p.T139M−18%
Plasma transthyretin by TTR genotype — Amyloidogenic variant heterozygotes vs p.T139M−29%
  • Plasma transthyretin by TTR genotype: P for trend < .001
  • Mortality by plasma transthyretin <20 vs 20 to 40 mg/dL in noncarriers (observational): n = 19 619

Original publication

Transthyretin Tetramer Destabilization and Increased Mortality in the General Population. JAMA Cardiol. Published 1 February 2025. doi:10.1001/jamacardio.2024.4102

Summarised from the published abstract; every number is checked against it